81 related articles for article (PubMed ID: 38538002)
1. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab deruxtecan in breast cancer.
Martín M; Pandiella A; Vargas-Castrillón E; Díaz-Rodríguez E; Iglesias-Hernangómez T; Martínez Cano C; Fernández-Cuesta I; Winkow E; Perelló MF
Crit Rev Oncol Hematol; 2024 Jun; 198():104355. PubMed ID: 38621469
[TBL] [Abstract][Full Text] [Related]
4. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
Ali A; Graff SL
Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
Ciruelos E; García-Sáenz JÁ; Gavilá J; Martín M; Rodríguez CA; Rodríguez-Lescure Á
Clin Transl Oncol; 2024 Jul; 26(7):1539-1548. PubMed ID: 38336982
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
Dannehl D; Jakob D; Mergel F; Estler A; Engler T; Volmer L; Frevert ML; Matovina S; Englisch A; Tegeler CM; Rohner A; Seller A; Hahn M; Pfister K; Fink A; Popp I; Lorenz S; Tabatabai G; Juhasz-Böss I; Janni W; Brucker S; Taran FA; Hartkopf A; Schäffler H
ESMO Open; 2024 May; 9(5):102995. PubMed ID: 38636292
[TBL] [Abstract][Full Text] [Related]
8. [Recurrent Breast Cancer with Pulmonary Lymphangitis Carcinomatosis Case Responding to Trastuzumab Deruxtecan].
Sugimoto T; Mizuta M; Fukui Y; Endo S; Tsubono M; Tsubono M
Gan To Kagaku Ryoho; 2024 May; 51(5):571-574. PubMed ID: 38881071
[TBL] [Abstract][Full Text] [Related]
9. Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan.
Neupane N; Thapa S; Bhattarai A; Ahuja K; Schlam I; Mittal A; Tolaney SM; Tarantino P
Curr Oncol Rep; 2023 Dec; 25(12):1467-1482. PubMed ID: 37938529
[TBL] [Abstract][Full Text] [Related]
10. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Guarneri V; Passos Coelho JL; Duhoux FP; Egle D; García-Sáenz JÁ; Penault-Llorca F; Selander K; Wildiers H; Zaman K; Laeis P; Lucerna M; Pierga JY
Future Oncol; 2024 Apr; ():1-14. PubMed ID: 38592002
[TBL] [Abstract][Full Text] [Related]
11. Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer.
Liu J; Zhu T; Zhao R; Ren W; Zhao F; Liu J
Gastric Cancer; 2024 May; 27(3):495-505. PubMed ID: 38386239
[TBL] [Abstract][Full Text] [Related]
12. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.
Vasalou C; Proia TA; Kazlauskas L; Przybyla A; Sung M; Mamidi S; Maratea K; Griffin M; Sargeant R; Urosevic J; Rosenbaum AI; Yuan J; Aluri KC; Ramsden D; Hariparsad N; Jones RDO; Mettetal JT
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):994-1005. PubMed ID: 38532525
[TBL] [Abstract][Full Text] [Related]
13. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.
Curigliano G; Dent R; Earle H; Modi S; Tarantino P; Viale G; Tolaney SM
ESMO Open; 2024 Apr; 9(4):102989. PubMed ID: 38613914
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone.
Pearson J; Khan A; Bhogal T; Wong H; Law A; Mills S; Santamaria N; Bishop J; Cliff J; Errington D; Hall A; Hart C; Malik Z; Sripadam R; Innes H; Flint H; Langton G; Ahmed E; Jackson R; Palmieri C
ESMO Open; 2023 Dec; 8(6):102033. PubMed ID: 37866031
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
Isogai A; Nozawa K; Nakakami A; Komaki R; Ozaki Y; Endo Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38797792
[TBL] [Abstract][Full Text] [Related]
16. HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.
Kapil A; Spitzmüller A; Brieu N; Haneder S; Shumilov A; Meier A; Cecchi F; Barkell A; Harder N; Mittermaier K; Hidalgo-Sastre A; Alleze R; Schick M; Schmidt G; Sade H; Tsuchihashi Z; Suto F; Gustavson M; Barrett JC; Carroll D
Sci Rep; 2024 May; 14(1):12129. PubMed ID: 38802399
[TBL] [Abstract][Full Text] [Related]
17. DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts.
Morinaga S; Han Q; Kubota Y; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
Anticancer Res; 2024 Jun; 44(6):2359-2367. PubMed ID: 38821601
[TBL] [Abstract][Full Text] [Related]
18. Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance.
Morgovan C; Dobrea CM; Butuca A; Arseniu AM; Frum A; Rus LL; Chis AA; Juncan AM; Gligor FG; Georgescu C; Ghibu S; Vonica-Tincu AL
Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790915
[TBL] [Abstract][Full Text] [Related]
19. Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report.
Suzuki N; Odawara N; Fujisawa G; Ishibashi R; Hata M; Oya Y; Tamada K; Hayashi T; Abe S; Miyakawa Y; Hayakawa Y; Shinozaki-Ushiku A; Ushiku T; Boku N; Fujishiro M
Intern Med; 2024 Jun; ():. PubMed ID: 38839335
[TBL] [Abstract][Full Text] [Related]
20. The potential of methioninase for cancer treatment.
Abo Qoura L; Balakin KV; Hoffman RM; Pokrovsky VS
Biochim Biophys Acta Rev Cancer; 2024 Jul; 1879(4):189122. PubMed ID: 38796027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
